ArticleInvestigational new drugs2010
Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent.
Article in Investigational new drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 17 citations in OpenAlex.
- Injectable Hydrogels for Cancer Therapy over the Last Decade.Pharmaceutics · 2019Review
- Simultaneous monitoring of the drug release and antitumor effect of a novel drug delivery system-MWCNTs/DOX/TC.Drug delivery · 2017Article
- Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.Surgery today · 2014Review
- Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.Surgery today · 2014Article
- The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.Investigational new drugs · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current systemic chemotherapy in the treatment of solid tumors inevitably induces various systemic adverse effects. Locally injected chemotherapy is expected to overcome this limitation of systemic therapy. We evaluated by luminescence imaging the effects of chemotherapy administered locally by means of a biodegradable thermosensitive hydrogel polymer. The human gastric cancer cell line HSC44Luc was used for tumor induction, and it was confirmed to be sensitive to doxorubicin by MTT assay. Cells were injected subcutaneously into Balb/c-nude mice. When the mean volume of tumor reached 400 mm(3), we divided the mice into 6 groups (5 per group) according to treatment: 1) control (intratumor injection of PBS), 2) systemic injection of doxorubicin, 3) intratumor injection of polymer gel, 4) intratumor injection of polymer gel physically mixed with a low dose of doxorubicin, 5) intratumor injection of polymer gel physically mixed with a high dose of doxorubicin, 6) intratumor injection of conjugated polymer gel with doxorubicin. Body weight and tumor volume were measured every 2 or 3 days for 30 days after treatment. One mouse in each group was sacrificed for histopathologic examination every week. Reductions in body weight were not significantly different among groups. The relative rate of tumor growth was 774% in Group 1, 267% in Group 2, 813% in Group 3, -186% in Group 4, and 155% in Group 6, respectively. Thus the relative rate of tumor growth in the groups treated with polymer gel mixed with doxorubicin and the groups treated with conjugated polymer gel with doxorubicin were lower than that in the control group. Locally injectable chemotherapy using a thermosensitive hydrogel polymer with doxorubicin can suppress tumor growth effectively without severe systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.